Addex mglu2 nam cognition program receives €4 million grant

Addex led consortium wins eurostar s grant to deliver clinical candidates to treat mild neurocognitive disorder s ad hoc announcement pursuant to art. 53 lr geneva, switzerland, september 20, 202 3 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has led a consortium which has been awarded a €4 million eurostars grant to support its metabotropic glutamate 2 (mglu2) receptor negative allosteric modulator (nam) program for mild neurocognitive disorder (mncd).
ADXN Ratings Summary
ADXN Quant Ranking